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  Several types of cancer including solid tumors and blood malignancies are associated 
with alterations in different regions of chromosome 6. In particular, the 6q region has been frequently 
found to be deleted in a wide range of solid tumors, including ovarian carcinoma. Therefore, this 
chromosomal region has been extensively investigated in order to identifying putative tumor suppressor 
genes. In specific, a minimal region of deletion for ovarian cancer has been defined in the peritelomeric 
6q27 region, and our group has recently isolated from this region the RNASET2 gene, coding for a 
secreted ribonuclease belonging to the Rh/T2/S acid ribonuclease family. 
The RNASET2 gene was found to be down-regulated at the transcriptional level in several primary 
ovarian tumors and ovarian cancer cell lines and its potential for tumor growth inhibition has been 
subsequently tested in vivo in a highly tumorigenic and metastatic Hey3Met2 ovarian cancer cell line. 
To this aim, athymic mice were injected with Hey3Met2 cell clones stably transfected with expression 
vectors encoding wild-type or a catalytically inactive mutant RNASET2 protein. Strikingly, wild-type 
RNASET2-expressing cells formed smaller tumors in mice and gave rise to a lower number of metastasis 
when compared to control cells transfected with the vector only. Moreover, mutant RNASET2-expressing 
cells also displayed a similar or even more increased inhibition of tumorigenicity when compared to wild-
type RNASET2, suggesting that catalytic activity is not involved in control of tumor suppression and 
metastasis. 
With the purpose of further defining the biological role of RNASET2, we have undertaken a functional 
characterization of this gene, by comparing RNASET2-overespressing cells behavior both in vitro and in 
vivo. In sharp contrast with previous in vivo observations, several in vitro tests such as proliferation, 
clonogenicity, growth in soft agar and apoptosis assays failed to reveal any change in cancer-related 
phenotypes in the same RNASET2-overexpressing cell line, thus suggesting a non-cell autonomous 
activity for RNASET2 as a tumor suppressor. 
This “asymmetric” in vivo/in vitro property has been recently ascribed to a novel class of tumor 
suppressor genes, called tumor antagonizing genes (TAGs), whose oncosuppressive activity is carried out 
only in vivo by induction of microenvironmental remodeling. 
To confirm this hypothesis we turned to a xenograft assay and, as expected, Hey3Met2 cells expressing 
wild-type or mutant RNASET2 were not able to support tumor growth when compared to control mice. 
Strikingly, a detailed histological analysis of tumor sections revealed a different architectural pattern 
between control mice and RNASET2-expressing tumors. The former showed a solid and diffuse growth 




massive infiltration of host stromal cells mainly derived from monocyte/macrophage lineage has been 
found. 
In order to establish whether these cells could be functionally responsible for RNASET2-mediated tumor 




 mice was performed, since these mice lack 
both lymphocytes and NK cells, thus retaining innate immunological response only through macrophages. 
As previously observed in nude mice, RNASET2-expressing cells were again clearly suppressed in 
tumorigenicity, further suggesting a functional role for macrophages recruitment in tumor suppression 
mediated by RNASET2. 





 mice were pretreated with the macrophages-depleting agent clodronate before inoculation of 
Hey3Met2 cells. Untreated mice showed once again a clear effect of tumor suppression exerted by 
RNASET2 whereas in clodronate-treated mice a very similar tumor development was noticed in both 
control and RNASET2-expressing cells. Finally, immunohistochemical analysis showed that recruited 
immune cells mainly belong to M1 subtype of anti-tumorigenic macrophages, suggesting a possible 
mechanism of tumor suppression exerted by this secreted ribonuclease. 
In order to extend RNASET2 functional characterization, beside the experimental model described above 
a complementary research approach based on gene silencing was carried out, aimed at studying how the 
lack of RNASET2 could affect tumor development and providing a powerful tool for further 
investigations. 
Our working hypothesis considers RNASET2 inactivation as a critical step in ovarian cancer progression, 
therefore cancer cell lines endowed with a low in vivo tumorigenic potential and expressing high 
endogenous RNASET2 levels might represent an ideal model system to challenge this hypothesis. In such 
a context, RNAi-mediated gene knockdown could provide additional information on this topic. 
RNAi-mediated silencing of the RNASET2 gene has therefore been attempted in the human ovarian 
carcinoma cell line OVCAR3, which displays the above mentioned features. 
Complete knockdown of RNASET2 in OVCAR3 cell line was successfully achieved and preliminary in 
vitro tests are in keeping with our previous data, showing no significant differences in proliferation and 
clonogenic potential in vitro in RNASET2-silenced when compared to control clones, and further 
supporting a “non-cell autonomous” behavior of RNASET2. 
Gene silencing of RNASET2 also allowed us to studying both the intracellular routing and likely the 
mechanism(s) by which extracellular RNASET2 affects in vivo cell behavior, demonstrating that 
providing an external source of RNASET2 to silenced OVCAR3 cells resulted in the binding of the 















2.1 Overview on molecular basis of cancer 
 
  A major feature of all higher eukaryotes is the defined life span of the organism, a 
property that extends to the individual somatic cells, whose growth and division are highly regulated. An 
exception is provided by cancer cells, which arise as variants that have lost their usual growths control. 
Their ability to grow in inappropriate locations or to propagate indefinitely may be lethal for the 
individual organism in which they occur. 
The basic model for the occurrence of cancer postulates a multistage process, in which initiation of tumor 
requires several steps which may then be followed by further changes to strengthen the tumorigenic state. 
Tumor progression is then driven by selection among the tumor cells for those that can grow more 
aggressively. Many different types of events are known to contribute to this process at the molecular 
level. The two major types of changes in the genome of cancer cells are the accumulation of somatic 
mutations and the development of genetic instability that overall is reflected at the cellular level by an 
uncontrolled proliferation together with a suppression of apoptosis. 
 
The two classes of genes in which mutations have been linked to cell transformation are oncogenes and 
tumor suppressor genes. 
Oncogenes were initially identified as genes carried by viruses that causes transformation of their target 
cells. It was found later that a major class of the viral oncogenes have cellular counterparts that are 
involved in normal cell functions. The cellular genes were called proto-oncogenes, and in certain cases 
their mutation or aberrant activation in the cell to form an oncogene was associated with tumor formation. 
The oncogenes fall into several groups, representing different types of activities ranging from 
transmembrane proteins to transcription factors, growth factors and growth factor receptors, signal 
transduction proteins, cell cycle regulators and regulators of apoptosis. 
 
The generation of an oncogene represents a gain-of-function event in which a cellular proto-oncogene is 
inappropriately activated. This can involve a mutational change in a protein’s coding region, or a 
constitutive activation, overexpression, or failure to turn off the oncogene expression at the appropriate 
time. 
Tumor suppressor genes (TSGs) encode proteins whose deletion, repression, expression inactivation, or 
mutation promotes oncogenesis. In some instances, reactivation of the function of a TSG suppresses the 
malignant phenotype. This type of TSG usually is referred to as a gatekeeper gene. 
Like oncogenes, tumor suppressor genes encode molecules involved in the regulation of cell proliferation. 




proto-oncogenes but, unlike oncogenes, tumor suppressor genes act in a recessive manner, requiring in 
the majority of cases that both copies of alleles are mutated before an effect is manifested. 
Inactivation of the other TSGs, namely caretaker genes, leads instead to genomic instability and therefore 
to an increase in the mutation of other genes that may be gatekeeper genes or influence tumor 
development. Caretaker genes include those involved in DNA repair or genes that maintain the integrity 
of chromosomes and their numbers. Unlike gate keeper genes, reconstitution of caretaker genes fails to 
override these secondary effects and does not suppress malignancy. 
Tumor suppressor genes are altered via different mechanism, including deletions and point mutations, 
which may also result in an inactive or dominant negative product. Regions of chromosomes frequently 
deleted in tumor cells are thought to harbor TSGs. Often such deletions are easily detectable and provide 
a means to map the underlying mutant gene. Alternatively, methylation of the promoter of a TSG can 
down-regulate its expression. Dysregulation of genes encoding proteins that modulate tumor suppressor 
may also lead to a defect in a given tumor suppressive function. In other examples, chimeric proteins 
formed by chromosomal translocations can produce dominant negative factors that can decrease 
expression, stability or function of TSGs. 
In a broad sense, any gene that can protect cells from progressing toward neoplastic growth can be 
considered a TSG, but in recent years several studies suggested that the suppression of cellular growth 
and the suppression of tumor-forming ability are controlled by different classes of genes (1). 
Thus, the canonical definition of TSG could encompass both genes that control cell cycle and 
proliferation (like p53, RB or that regulate apoptosis) and genes that antagonize with malignancy onset 
and development, a feature that has a clear meaning in vivo but is difficult to translate into in vitro 
contexts (1, 2). 
Tumor antagonizing genes (TAGs) have been historically identified from hybrids generated by cell fusion 
of normal with tumor cells and selected in vitro for positive growth and suppression of apoptosis, but in 
vivo they did not produce tumors (3). Moreover, later studies showed that somatic hybrids obtained by 
single chromosomes transfer from non-cancer cells could suppress tumorigenicity by themselves only in 
vivo, and the reappearance of tumorigenic phenotype was associated in a loss of chromosomal regions 
that did not harbor the “classical” aforementioned p53 and RB (4, 5). 
The most salient feature of TSGs is therefore their ability to suppress tumor growth in vivo but not in 
vitro, and as such “asymmetric” behavior could be explained by virtue of complex interactions network 
that in vivo constitute the microenvironmental milieu (cellular and humoral) of the tumor. 
A deeper investigation of biology of tumors has indeed clarified that stromal cells that constitute the 
tumor microenvironmental (fibroblasts, myofibroblasts, endothelial cells, macrophages, lymphocytes) are 
essential collaborators of the neoplastic process, which can be recruited and exploited by the cancer cell 
itself (6, 7). Cancer cells generate a supportive microenvironment by producing stromal-modulating 
growth factors. These include basic fibroblast growth factor (bFGF), members of the vascular endothelial 




(EGFR) ligands, interleukins, colony-stimulating factors, transforming growth factor-β (TGFβ) and 
others. These factors disrupt normal tissue homeostasis, similar to the processes of wound healing, and 
act in a paracrine manner to induce stromal reactions such as angiogenesis and the inflammatory 
response. The factors also activate surrounding stromal cell types, such as fibroblasts, smooth-muscle 
cells, and macrophages, leading to the secretion of additional growth factors and proteases (8, 9, 10). 
This general framework means that cancer development is not simply a cell-autonomous process, but 
represents instead a complex event based on continuous communication between cancer cells and the 
surrounding non-neoplastic tissue, suggesting that carcinogenesis should be regarded as a tissue disease 
rather than an individual cell disease (8). 
In this context TAGs could take part by interacting with tumor environment (stromal cells, extracellular 
matrix, soluble signals) and inhibit tumor growth by at least three general processes such as response to 
differentiation-inducing signals, inflammation signals (eliciting immune response) and angiogenesis 
inhibition (5). 
Among the TAGs recently discovered are HYAL1 and HYAL2, encoding for hyaluronidases (11), and 





2.2 Ribonucleases and cancer 
 
  Ribonucleases (RNases) represent an heterogeneous class of evolutionarily conserved 
enzymes, whose main biological role is involved in RNA metabolism. From a biochemical perspective, 
RNases degrade RNA through hydrolysis of single-stranded and double-stranded RNAs or RNA-DNA 
hybrids, but their biological roles include a variety of cellular processes ranging from cytoplasmic or 
nuclear RNA degradation, RNA processing and editing, gene expression, antiviral defense, angiogenic, 
neurotoxic and immunosuppressive functions (13). 
Furthermore, the most interesting properties include cytotoxic and anticancer activities owned by some 
classes of ribonucleases, thus placing them as promising alternative to conventional chemotherapy (14); 
these features are described below with a particular emphasis. 
A particular group of ribonucleases are transferase-type RNases, which hydrolyze single-stranded RNA 
via a 2’,3’-cyclic phosphate intermediate, forming oligo- or mononucleotides with a terminal 3’-
phosphate. They can be classified in several ways, according to substrate or base specificity, optimal pH 
for activity, cellular localization, origin and sensibility against inhibitors; however the main classification 
distinguishes between alkaline RNases (with an optimal pH activity of 7.0 and 8.0) which include A and 
T1 families and acid ribonucleases (pH activity 4.0 to 5.0), belonging to T2 family (15). 
 
Alkaline ribonucleases 
Alkaline RNases are characterized by a low molecular weight and an optimal pH for catalytic activity 
around 7.0-8.0, and are classified into two main subfamilies: RNase A and RNase T1. 
T1 RNases are widely distributed in fungi and bacteria, have a molecular mass of about 12 kDa and show 
cutting specificity for guanine. 
Although the most known role for these enzymes is digestive, an important T1 RNase member endowed 
with anticancer activity is Binase, a 12 kDa bacterial protein isolated from Bacillus intermedius. 
This enzyme displays a wide spectrum of activities against malignant cells, with selective apoptosis-
inducing activity on human myelogen erythroleukemia K562 cells, human lung carcinoma A549 cells and 
human peripheral blood mononuclear cells (16). 
Most information about antitumor ribonucleases came from studies on members of the pancreatic-type 
ribonuclease superfamily (RNase A family). Enzymes belonging to this family of ribonucleases (which 




they have mainly a digestive function, a molecular mass ranging between 13 and 14 kDa and cutting 
preference for pyrimidines (15). 
Among these ribonucleases, bovine seminal RNase (BS-RNase), RNase from oocytes of Rana pipiens 
(commercially named Onconase) and two closely related frog RNases from Rana catesbiana and Rana 
japonica eggs are of particular interest for their anti-oncogenic activity. 
Only in recent years the molecular basis underlying their cytotoxicity is becoming clear. Based on the 
result obtained so far, a multi-step model has been generally accepted which predicts that cytotoxicity 
requires these RNases to interact with the cell membrane and to be internalized by endocytosis. 
Then cytotoxic RNases are translocated to the cytosol where they cleave cellular RNAs, inducing 
apoptosis. 
The cytotoxic effects and anticancer properties of BS-RNase are well documented (17-20). This RNase 
shows selective anticancer activity against several tumor cells including thyroid carcinoma cells, 3T3 
fibroblast cells (both in vitro and in vivo), ML-2 myeloid cells and NB-1 and NB-2 neuroblastoma cells. 
Its selectivity for malignant cells has not been explained yet. Since BS-RNase is endocytosed in 
malignant and non-malignant cells to the same extent, a different internalization pathway between cancer 
and normal cells has been proposed (21). To date, no specific receptors have been found for this RNase 
on the cell surface and it has been suggested that BS-RNase is able to enter cells by adsorption, although 
involvement of extracellular matrix has been clearly demonstrated (22). Once BS-RNase is delivered in 
the cytoplasm, its dimeric nature (due to both intermolecular disulfide bonds and non-covalent 
interaction) prevents its binding to cytosolic ribonucleases inhibitors, increasing cytotoxic activity. The 
latter is exerted by blocking protein synthesis via rRNA cleavage followed by caspases 8/9 mediated 
apoptosis (17). 
Another notable representative member of cytotoxic ribonucleases is Onconase, the smallest member 
RNase A superfamily, known to be highly cytotoxic to cancer cells (23, 24), and to possess in vivo 
anticancer activity (18). Currently it is under phase III clinical trials for unresectable malignant 
mesothelioma (14). Onconase works in a similar way to others cytotoxic RNases, acting inside of the 
cells where it cleaves RNA and trigger apoptosis. Its binding to cell surface in non-saturable way is 
consistent with the absence of specific receptors, and it was therefore suggested that interaction with 
plasma membrane occurs electrostatically between negative charges of outer leaflet of cell and positive 
charges on Onconase surface. Within this frame, it is worth mentioning that cytotoxic RNase obtained by 
conjugation or fusion of non-cytotoxic RNases to cell membrane ligands, such as transferrin, growth 
factors or antibodies, are more efficiently taken up by the target cells and, consequently acquired 
cytotoxic properties (25). Moreover, since the surface of most cancer cells is more electronegative 
compared to normal cells (26) electrostatic interactions between negative charged cell membrane and 




After internalization by endocytosis, the ribonucleolytic activity of Onconase is allowed by means of both 
resistance to RNases inhibitor and a high conformational stability due to a pyroglutamyl residue at the N-
terminus and a disulfide bridge at the C-terminus. However, the fine mechanism by which Onconase 
triggers apoptosis is not completely understood and is still controversial (27). It was initially postulated 
that rRNA and then tRNA whose cleavage causes translational block and thus induces apoptosis were the 
targets of Onconase. Nevertheless further studies showed that these mechanisms were incompatible with 
the observed Onconase effects. Indeed, treating cells with a translation inhibitor such as cycloheximide, 
leads to a complete different pattern of phenotypical and molecular changes compared to Onconase 
treated cells; moreover Onconase initially induces G1 arrest and apoptosis occurs with a 24-48 hours 
delay, whereas cycloheximide kills cells indiscriminately in the cell cycle. Finally, the proteins coded by 
several genes (of which some are involved in regulation in cell cycle progression) are up-regulated after 
treatment with Onconase. Therefore Zhao and colleagues had suggested that one of the targets of 
Onconase is the non-coding RNA (microRNAs) that is involved in regulation of gene expression through 
RNA interference (28). 
In human, eight genes encoding catalytically active RNases belonging to the A superfamily (numbered 1 
to 8) were identified (29). Despite several information about their biochemical properties are available, 
the physiological roles of many of them still have to be elucidated. 
Among them RNase 5, also called angiogenin, is one of the best characterized enzymes. Angiogenin has a 
wide tissue and organ distribution and its potent blood-vessel inducing activity suggests that in may play 
a role in embryologic, neoplastic, inflammatory and immunogenic angiogenesis. Its enzymatic activity as 
a ribonuclease is essential for angiogenesis; most probably such an activity is performed inside the cell 
and particularly in the nucleolus, where it is involved in ribosomes biogenesis (30).  
Worth mentioning are also RNase 2 and 3, previously known as eosinophil-derived neurotoxin (EDN) 
and eosinophil cationic protein (ECP), the major secreted proteins of eosinophil granules endowed with 
antimicrobial, antiviral and antiparasitic activities. Unlike RNase 3, which is an eosinophil specific 
protein, RNase 2 has also been found in other tissues such as spleen, liver, kidney and placenta and 
interestingly it has been included in the novel class of proteins called alarmins for its ability to promote 














The name “acid RNases” is currently used for two types of RNases in literature. 
One type includes pyrimidine base-specific RNases, which are distributed in the vertebrate liver, spleen, 
urine, monocytes, and other tissues. They have a primary structure similar to RNases A and due to 
optimal pH activity of 6.5 – 7.0 they are referred as “weakly acid” ribonucleases (15). 
To the other type of acid RNases belongs the Rh/T2/S family, with an optimal pH of 4.0 – 6.0 (thus are 
considered “real acid” RNases) and a molecular weight between 20 kDa and 40 kDa. 
Rh/T2/S ribonucleases are secreted glycoproteins represented in most organisms across kingdoms, being 
widely distributed in protozoans, plants, bacteria, animal and viruses. The name of the family (often 
simply referred as “T2”) derived from the most studied ribonucleases within this family which include 
RNase Rh of Rhizopus niveus, RNase T2 from Aspergillus oryzae, and S-glycoproteins isolated in higher 
plants. Depending on the organism they are found, they are involved in various functions such as role in 
the pathogenesis, phosphate remobilization, defense against pathogens and self-incompatibility in plants 
(15). As well as ribonucleases A-type, they catalyze the cleavage of single stranded RNA through a 2’,3’-
cyclic phosphate intermediate, producing mono- or oligonucleotides with a terminal 3’ phosphate group. 
A shared important feature of all Rh/T2/S glycoproteins is the presence of two highly conserved common 
motives named CAS I and CAS II (Conserved Active Site segment), harboring the catalytic activity. In 
CAS I (IHGLWP) and CAS II (KHGTC) amino acid residues critically involved in the catalytic activity 
(such as His 46, His 104, His 109 and Glu 105 in RNase Rh numbering) are located (32). Moreover, four 
cysteine residues forming disulfide bonds are common to all RNases of T2 family, conferring to Rh/T2/S 
RNases a very compact and stable structure. 
The majority of the T2 family RNases are glycoproteins, showing a wide range in their carbohydrate 
content. In general, N-glycosylation occurs at the consensus sequence Asn-X-Thr/Ser (O-glycosylation is 
rare) and in most cases the glucidic moiety is made up of glucose, mannose and glucosamine (32). 
Due to the widespread diffusion in all organism, RNase T2 functions and cellular localization are very 
different. 
In fungi, extracellular T2 RNases are reported to have a role in nutrition by scavenging nucleotides and 
phosphate for growth and metabolism. In higher plants an analogous activity has been reported, since 
phosphate starvation causes an increase of S-like RNases localized in vacuole and extracellular 
environmental. Secreted RNases scavenge extracellular RNA and recycle its components to the cell, 
whereas vacuolar RNases also function in recycling of cytoplasmic RNAs that are delivered to the 
vacuole/lysosome during autophagy (33). 
Another interesting function is associated to stylar S-RNases, known for their role in gametophytic self-
incompatibility (a system through which genetically related-pollen is recognized and rejected prior to 




extracellular S-RNases are pistil proteins that are secreted into the extracellular matrix and enter in both 
incompatible and compatible pollen tubes. 
The pistil then distinguishes between self and non-self pollen, based on whether or not the S-allele of the 
haploid pollen matches either of the two S-alleles of the diploid pistil and matching results in rejection. S-
RNases are secreted by ovary cells and act as cytotoxins: they enter the pollen tube cytoplasm and interact 
with SLF, an F-box domain that contains proteins able to mediate polyubiquitination. In a compatible 
pollination, non-self interaction leads to S-RNase degradation by the 26S proteasome; otherwise, in an 
incompatible pollination S-RNases evade SLF control and degrade rRNA, inhibiting the growth of self-
pollen tubes (34). 
Another example of T2 RNases with cytotoxic activity comes from classical swine fever virus (CSFV) 
(33). In this virus, one of the envelope glycoproteins, termed E
rns
, has an RNase T2 domain and 
ribonuclease activity, and is secreted by infected cells. In vitro, this enzyme produces a selective 
cytotoxic effects against lymphocytes, suggesting that virally infected cells secrete E
rns
 to reduce the host 
immune response. 
Interestingly, some T2 RNases seem to play a biological role in a catalytic-independent manner. 
In yeast (35), during oxidative stress Rny1p (homologous to the human RNASET2 gene) is released from 
the vacuole and cleaves cytoplasmic tRNAs and rRNAs, by means of its catalytic activity. Nevertheless, 
Rny1p also modulates yeast cell survival during oxidative stress, resulting in reduced cell viability and 
apoptosis, and this role is apparently carried out irrespective of the ribonucleolytic activity of the protein. 
Therefore the authors suggested that cellular response to stress involves two parallel pathways, in which 
release the vacuolar Rny1p functionally mimics cytochrome c release from mitochondria in higher 
eukaryotes. 
Another T2 ribonuclease that exhibits a catalytic-independent function is ACTIBIND, the extracellular 
RNase purified from Aspergillus niger. Unrelated to its RNase activity, ACTIBIND binds in vitro actin 
filaments, resulting in altered actin organization and cell morphology that in turn is reflected in reduced 
colony formation and motility of several tumor cell lines. In vivo it inhibits growth and metastasis in 
colon cancer and melanoma mouse model (36, 37) and shows angiogenesis inhibition both in vitro and in 





2.3 The human ribonuclease RNASET2 
 
  The peritelomeric region of the long arm of human chromosome 6 has been intensely 
investigated in recent years in order to find putative tumor suppressor genes. Indeed, a wide range of solid 
and hematological neoplasia, ranging from carcinomas of the ovary, breast, uterus, melanoma, non-
Hodgkin B-cell lymphoma and acute lymphoblastic leukemia have been associated to rearrangements and 
deletions in this region (38-43). Among the solid tumors, ovarian cancer has been deeply studied, because 
of mortality rate, mostly due to late diagnosis; moreover, little is known about the genetic pathways 
underlying its development. By employing LOH analysis with markers located on the long arm of 
chromosome 6, three consensus regions of loss of genetic material have been identified, namely 6q21-
23.3, 6q25.1-25.2 and 6q26-27 (44-46). In the latter region, later studies revealed the minimal 
chromosome region found deleted in ovarian tumors, flanked by markers D6S193 and D6S297 (47-49). 
Between these two markers, in a region that spans about 27 Kb maps the RNASET2 gene, coding for the 
only known human Rh/T2/S ribonuclease (50). 
RNASET2 is present in the human genome as a single copy gene, organized into nine exons and eight 
introns, and is expressed in almost all normal tissues, such as liver, ovary, lung brain, heart, placenta, 
kidney and skeletal muscle (50). 
The first indications for RNASET2 involvement in ovarian cancer came from gene expressions studies 
performed on many primary ovarian tumors, already known to contain 6q26-qter deletions in at least one 
of the chromosome 6 homologues. Decreased RNASET2 transcript levels where found in 30% of them, 
but neither inactivating mutations in the coding sequence, intron-exon boundaries, 5’ and 3’ flanking 
regions nor abnormally methylated CpG in the promoter region were detected, thus indicating a class II 
tumor suppressor behavior for this gene (50). 
A more direct evidence for RNASET2 control of tumor growth was subsequently obtained by transfecting 
RNASET2 cDNA in the ovarian cancer cell line Hey4 and testing for its ability for tumor formation in 
nude mice, showing a strong tumor growth inhibition (50). 
Remarkably, further in vivo characterization revealed that catalytic activity was dispensable for tumor and 
metastasis suppressions. In this study, athymic mice were injected with a highly metastatic ovarian 
Hey3Met2 cell line stably transfected with RNASAET2 wild-type or catalytically inactive mutant, 
obtained by means of substitution of amino acids critically involved in catalysis. Wild-type RNASET2-
expressing cells formed smaller tumors in mice and gave rise to a lower number of metastasis with 
respect to control cells transfected with the vector only. Moreover, mutant RNASET2 also displayed a 
similar or even more increased inhibition of tumorigenicity when compared to wild-type RNASET2, 




The RNASET2 gene encodes for an extracellular glycoprotein of 256 amino acids with a predicted 
molecular weight of 30 kDa. The protein contains a signal peptide for secretion at the N-terminal and 
three N-glycosylation sites are predicted to occur at positions 76, 106 and 212, increasing the molecular 
weight of about 6 kDa. Like other Rh/T2/S glycoproteins, two highly conserved CAS segments are found 













Figure 1. RNASET2 protein structure 
Full length RNASET2 is characterized by a signal peptide located at N-terminal position, (ranging from amino acid 1 to 
24), two active site segments (CAS I and CAS II) highly conserved among T2 family ribonucleases and three N-
glycosylation sites bioinformatically predicted at positions 76, 106 and 212. In the RNASET2 H65/118F mutant, two 
essentials histidines (red letters) for catalysis are substituted with two phenylalanines, leading to a catalytically inactive 
form. 
 
In cell lysates RNASET2 is present in three forms of different sizes, namely 36, 31 and 27 kDa. The 36 
kDa isoform represents the full-length and secreted form, whereas the other two isoforms likely originate 
from proteolytic cleavage occurring at C-terminal. All three forms are glycosylated, since treatment of 
intracellular lysates with PNGase F resulted in a proportional shift toward a lower molecular weight (36, 
31, and 27 kDa forms shifted to 31, 23 and 19 kDa respectively) (52). 
Subcellular fractionation followed by immunoblot revealed that the RNASET2 full-length form is 
enclosed in the endoplasmic reticulum, while the two proteolytic forms were detected in the lysosomal 
fraction, indicating that RNASET2 is targeted as a full-length form to the secretory pathway but 
undergoes proteolytic cleavage during transport or delivery to the lysosome. The catalytic activity has 
also been investigated, showing that RNSET2 cleaves with an optimal pH at 5 either total RNA or tRNA 
and glycosylation is not required for catalysis. In contrast with most members of Rh/T2/S family, some 
base specificity has been reported since poly-U and poly-A oligonucleotides were preferentially cleaved 














K H G T C
 121
 
1       24 256 

















wild-type H65/118F control 
   
43 kDa -  
34 kDa -  
26 kDa -  
55 kDa -  
3.1 In vitro cell based assays 
 
  In a previous work, RNASET2 has been defined as a candidate oncosuppressor gene by 
means of its ability to suppress tumor growth in vivo once overexpressed in the highly oncogenic and 
metastatic Hey3Met2 ovarian cancer cell line (51). Such tight control of in vivo tumorigenesis raised the 
question whether RNASET2 could exert its antitumorigenic role in a cell-autonomous manner, as already 
described for other tumor suppressor genes. 
For this purpose, several in vitro test were performed, by comparing a wide range of cancer-related 
phenotypes in RNASET2-overexpressing cells compared to Hey3Met2 control clones. 
Four stable transfected control clones carrying the pcDNA3 empty vector and eight RNASET2-
expressing stable transfected clones with the same level of expression of RNASET2 wild type or 













Figure 2. Immunoblot probed with polyclonal antibody anti-RNASET2 
Upper panel: intracellular lysates of Hey3Met2 are checked for RNASET2 expression. Control clones show a very low 
level of endogenous expression. 
Lower panel: the same blot was probed with anti-α-tubulin monoclonal antibody for normalization. 
 
 
The first parameter analyzed was the cell growth kinetic, in order to assess if the strong RNASET2-





































Four Hey3Met2 clones were plated in triplicate in a 24 well culture plate for each construct (namely 
pcDNA3 empty vector, pcDNA3-RNASET2 wild type or pcDNA3-RNASET2 H65/118F mutant) and 














Figure 3. Growth curve 
The graph represents the mean of values of each group of clones. Rumble: pcDNA3 vector; squares: pcDNA3-RNASET2 
wild type; triangles: pcDNA3-RNASET2 H65/118F mutant. Bars indicate the standard error. 
 
As shown in figure 3, we could not detect any statistically significant difference in the proliferation 
kinetic among the analyzed clones. 
From these raw data, the population doubling time was also calculated, resulting in almost identical 













Figure 4. Doubling time 
The mean of doubling time for each group of clones is 19 hours, with only few tens of minutes of difference between 























Although the analysis of growth curve kinetics ruled out any difference between RNASET2-expressing 
and control clones, this kind of test simply describes a steady state of total cells number in culture, and is 
therefore not informative about dynamic events affecting cell behavior in vivo or in vitro. 
Such processes, like proliferation and apoptosis, could balance their opposite effects so that cells in 
culture apparently grow to the same extent but have very different behaviors in relation to these two 
parameters. To examine this possibility, bromodeoxyuridine (BrdU) incorporation and TUNEL apoptosis 











Figure 5. BrdU incorporation 
Actively proliferating cells incorporate BrdU as thymine analog during DNA synthesis and then are labeled with specific 
antibody. Positive cells are then manually counted by microscope. Bars indicate the standard deviation. 
 
The bromodeoxyuridine incorporation assay revealed that all clones were proliferating to the same extent, 
with a fraction of proliferating cells of about 20%. The same result was obtained when apoptosis rates 










Figure 6. TUNEL apoptosis assay 
Cells are seeded on coverslips and the day after are fixed in paraformaldehyde. After permeabilization TdT reaction is 
detected by streptavidin-HRP conjugated, by using DAB as chromogenic substrate. 
In the reported images dark brown cells are apoptotic ones. The percentage of apoptosis is around 3% for each clone. 
A – pcDNA3 vector; B – pcDNA3-RNASET2 wild type; C – pcDNA3-RNASET2 H65/118F mutant. 




The results from both proliferation rate and apoptosis assays showed no statistically significant 
differences among the different experimental groups, indicating that RNASET2 actually does not affect 
the rate of cell growth in vitro. 
 
Within solid tumors, very often only a small fraction of the cells are actively proliferating (hence giving 
rise to colonies), and so are directly responsible of the tumor growth (53). To investigate the effect of 
RNASET2 on the colony-forming ability of Hey3Met2 cells, an in vitro clonogenic assay was performed, 
but differences in neither colony number nor size were detected in Hey3Met2 RNASET2-expressing and 










Figure 7. Clonogenic assay 
Cells were plated in 6-well culture plates (2 x 10
2
 cells per well) and following 14 days incubation, clones were stained 
with a methylene blue solution (1% methylene blue, 50% ethanol) and visible colonies were manually counted. 
A – pcDNA3 vector; B – pcDNA3-RNASET2 wild type; C – pcDNA3-RNASET2 H65/118F mutant. 
 
 
As an independent parameter to evaluate the transformed phenotype of RNASET2-expressing cells, 
anchorage-independent growth was also investigated. A typical feature of malignant cancer cells involve 
their ability to growth in vitro without adhering to a solid substrate. Indeed, transformed cells not only 
lose contact inhibition with neighboring cells to form foci, but also gain the ability to growth in 
anchorage-independent manner. This parameter can be easily tested by measuring the growth of isolated 
cancer cell colonies in soft agar, a semi-solid medium that usually does not support the growth non-cancer 
cells. When this assay was carried out with the Hey3Met2 clones, even though a slight variability among 
different clones transfected with the same construct was observed, no significant differences were once 

























































Figure 8. Soft agar growth 
To evaluate anchorage-independent growth, a two-layers soft agar test was performed. For each clone 100 cells were 
resuspended in 0.3% Bacto-Agar in DMEM F12 supplemented with 20% FBS and then plated over a layer of 0.6% Bacto-
Agar in DMEM F12 supplemented with 20% fetal bovine serum in 12 well culture plates. Colonies were counted after 14 
days. Bars indicate the standard deviation. 
 
 
Finally, RNASET2 was tested for its ability to mediate cell adhesion to an artificial membrane 
preparation (Matrigel), since a clear connection between tumor cells adhesion to the extracellular matrix 
and invasive and metastatic behavior has long been established (54). As shown in figure 9, the effects of 












Figure 9. Adhesion test 
Cells were plated on non-tissue culture plate previously coated with matrigel (5x10
3
 cells/clone, 10 wells/clone). 
After 4 hours of incubation the adhering cells were stained with crystal violet and absorbance value measured. 






Collectively, the results from this wide range of in vitro assays convincingly showed that RNASET2 does 
not influence any cancer-related parameter in vitro, thus suggesting a non-cell autonomous role for this 
gene. 
In this view, apparently RNASET2 is not able by itself to control the tumorigenic phenotype in the 
cellular context in which it is expressed, but would instead require a broader context of interactions, such 
as those that can be established in vivo between cancer cells and the tumor microenvironment.  
Subsequent investigations were therefore focused to this topic, with the aim to characterize the 
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3.2 Analysis of tumors from in vivo experiments on athymic mice 
 
  With the aim to better define the role of RNASET2 in vivo, a xenograft assay was 
carried out by inoculating in nude mice the same Hey3Met2 clones previously characterized in vitro. 
Thereafter, a detailed histological and immunohistochemical analysis of tumor specimens was performed. 
In keeping with our previous in vivo experiments, large tumors developed in control mice inoculated with 
Hey3Met2 clones transfected with the empty vector, whereas RNASET2-expressing clones showed a 
negligible increase in the tumor mass over time (figure 10). Moreover, mutant RNASET2-expressing 
clones were even more suppressed in tumorigenicity than wild-type expressing clones, thus further 
















Figure 10. Tumorigenicity test in vivo by xenograft in nude mice 
Hey3Met2 clones (5x10
6
 cells/clone) stably transfected with pcDNA3 control plasmid, wild type or mutant RNASET2 
were grafted by subcutaneous injection in athymic mice (5 mice/clone) and tumor growth was checked every two days. 
Bars represent the standard deviation values. 
 
 
To better investigate the cellular and molecular mediators of RNASET2-dependent tumor suppression, 
tumour specimens from the xenograft assay were isolated, formalin-fixed and paraffin-embedded for 
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We first verified that RNASET2 expression was maintained in vivo. To this end, an 
immunohistochemical (IHC) assay was carried out by immunostaining tumor sections with an anti-










Figure 11. RNASET2 is maintained in tumors sections 
Immunohistochemistry with anti-RNASET2 on tumours from athymic mice inoculated with Hey3Met2 transfected with 
vector only (A) or with constructs expressing wild-type (B) or mutant (C) RNASET2. Original magnification 100X. 
 
As shown in figure 11, control tumors showed an expected weak staining (arrows, image A), in keeping 
with the very low endogenous RNASET2 expression levels of Hey3Met2 cells. By contrast, the 
RNASET2 protein was clearly detectable in sections from tumors inoculated with cells transfected with 
both RNASET2 expression vectors, showing a granular signal in the cytoplasm of tumour cells which 
likely represents the secretory compartment. 
We next investigated the morphological features of RNASET2-expressing and control tumors sections. 
Hematoxylin and eosin staining (H&E, figure 12) showed that all tumors were characterized by the 
presence of two main cell populations with a different nucleus/cytoplasm ratio and basophilic affinity. 
Control tumors were characterized by a rather homogenous architecture, being made of a predominant 
population characterized by big cells with low nucleus/cytoplasm ratio (likely representing cancer cells) 
with only few cluster of intensely stained small cells of probable murine origin. 
By contrast, in RNASET2-expressing tumors a complete different tissue architecture was found, with the 
tumor mass sepimented by an abundant infiltrate of smaller intensely stained cells arranged in cordon-like 
structures. 
Moreover, in both wild-type and mutant RNASET2-expressing tumors a Masson’s trichrome staining 
showed that neoplastic cells were surrounded by bridges of accumulated connective tissue containing an 





























Figure 12. H&E staining reveals different tissue architecture among tumors 
Two main cell populations with can be distinguished, according to size and different staining. Furthermore, homogeneous 
and compact structure can be noticed in control tumors (A) whereas cordon-like structures (arrows) of host cells can be 
clearly see in RNASET2-overexpressing tumors (wild type, B, and mutant, C). Images are representative of multiple fields 
analyzed in at least six sections derived from tumors excised in three independent animals for each experimental group. 











Figure 13. Masson’s trichrome staining 
In wild type and mutant RNASET2-expressing tumors (B and C respectively) neoplastic cells are surrounded by 
connective tissue (stained in blue), whereas in control tumors (A) such component is absent. In the former tumors, 
between collagen fibers, a more intense staining of nuclei and cytoplasm reveals a population of host-derived cell, whose 
morphological analyses indicated to be mostly granulocytes and mononuclear cells. Original magnification 40X. 





Taken together, these data suggested that RNASET2-expressing tumors were associated with a massive 
cellular infiltrate derived from the host stromal compartment, and prompted us to better investigate this 
cell population. 
In order to verify that the infiltrating cell population observed in tumor sections was of murine origin, a 
chromogenic in situ hybridization (CISH) assay was performed by using a murine chromosome Y-
specific centromeric probe. This probe allowed us to identify only murine cells, since the inoculated 
human cancer cells were derived from ovarian carcinoma whereas the recipients mice were males. 
Strikingly, the CISH assay clearly demonstrated that the cell population infiltrating the tumors was 











Figure 14. Chromogenic in situ hybridization (CISH) reveals host-derived origin of infiltrating stromal cells 




Since a preliminary morphological analyses suggested that the host stromal cells segregating in 
connective strands within the neoplastic mass in RNASET2-expressing tumors might belong to the 
granulocytes/mononuclear lineage, an immunohistochemical assay was carried out to detect the CD11b 
antigen, (a component of the CD11b/CD18 integrin heterodimer that is expressed in natural killer cells, 
monocytes and granulocytes) and the F4/80 antigen (figure 15 A’-C’), a cell surface glycoprotein 
restricted to mature macrophages and therefore absent in granulocytes and lymphocytes. 
For both markers, a few reactive cells were detected in control tumors when compared to RNASET2-
expressing tumors, where a massive population of strongly reactive cells infiltrating the tumors (mostly 
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On the basis of these data, we established a novel working hypothesis by which RNASET2 could carry 
out its tumor suppressing activity by stimulating a massive recruitment into the tumor mass of cells from 


















Figure 15. Characterization of host infiltrating cells 
Upper panel: immunohistochemistry with anti-CD11b. 
Lower panel: immunohistochemistry with anti-F4/80. 
A massive infiltration of host immune system cells is detected in RNASET2-expressing tumors (brown spots) 
A, A’ – control tumor; B, B’ – wild type RNASET2-expressing tumor; C,C’ – mutant RNASET2-expressing tumor. 
Original magnification 40X. 
 
Having defined the cell population infiltrating RNASET2-expressing tumors, we then shifted our 
attention to the putative mechanisms behind RNASET2-mediated tumor suppression. To this aim, three 
main processes were investigated such as proliferation rate, apoptosis and vascularization. 
Tumor specimens were thus analyzed by immunohistochemistry with antibodies raised against activated 
caspases 3 (cleaved caspases 3, CCL-3), Ki-67 (a nuclear non-histonic protein expressed only by 
proliferating cells) and CD31, a specific component of endothelial cell junctions. 
As shown in figure 16, the majority of cells in control tumours were actively proliferating, whereas in 
RNASET2-expressing tumours (and particularly in those expressing the mutant form) a decreased 








pcDNA3 vector pcDNA3-RNASET2 wild-type pcDNA3-RNASET2 mutant 
By contrast, an opposite pattern was observed for CCL-3 staining, with an increased number of positive 
cells detected in wild-type, and even more in mutant-RNASET2 expressing tumors with respect to control 
tumors. 
Finally, in clear contrast to these observations, no apparent changes in blood vessel density and 

























Figure 16. Immunohistochemical detection of apoptotic, proliferating and endothelial cells in tumor samples 
Upper panel: immunohistochemistry with anti-active caspases 3 (original magnification 100X). 
Middle panel: immunohistochemistry with anti-Ki-67 (original magnification 40X). 
Lower panel: immunohistochemistry with anti-CD31 (original magnification 40X). 
Photomicrographs shown are representative images of multiple fields examined in at least four sections derived from 
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  The experimental data just described, obtained in an athymic mouse model, strongly 
suggest that macrophages might play a critical role in control of RNASET2-mediated tumor suppression. 





 mice has been carried out. 
These mice are devoid of lymphocytes, due to a mutations that inactivates the Rag genes (Recombination-
Activating Gene) encoding for key components of the lymphoid-specific recombinase. Moreover, a 
second mutation has been introduced in the gene coding for the "common γ chain” (γc) of many 
hematopoietin receptors, essential for the maturation and survival of lymphocytes, mast cells and NK-




 mice are endowed with a partial innate immune system 
response, represented by the monocyte-macrophage and granulocyte cell population. 




 mice and, as shown in figure 17, 
tumor development was strongly impaired in mice injected with RNASET2-expressing cells, whereas 
control tumors reached a tumor mass of 1300 mm
3
 in 19 days only. Thus, in vivo suppression of tumor 
growth carried out by RNASET2 irrespective of its catalytic activity was confirmed in a second 


























 mice (3 mice per clone) and tumor growth was checked every two day until day 19. 
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were treated with the macrophages-depleting agent clodronate before injection of Hey3Met2 clones. 
Clodronate (figure 18) is a non-toxic drug that accumulates intracellularly into phagocytic cells once 
delivered using liposomes as vehicles. 
Lysosomal phospholipases within phagocytic cells hydrolyze the phospholipid bilayers of the liposomes 
and clodronate is then released into the cell, where it rapidly accumulates until a threshold concentration 
is reached, after which the cell is irreversibly damaged and dies by apoptosis (55). 
By contrast, free clodronate, such as that released from dead macrophages, has an extremely short half-










Figure 18. Clodronate structure and mechanism 
Clodronate (1) is enclosed in liposomes (2) thus can easily pass the cellular membrane and be phagocytized by 
macrophages (3). In the cell, liposomes fuse with lysosomes (L) where phospholipases dissolve the lipid shell of 






 mice were either mock-treated or injected with clodronate liposomes (4 animals treated with 
clodronate and 4 untreated) before subcutaneous injection with Hey3Met2 control cells in the left flank 
and RNASET2-expressing Hey3Met2 cells (either wild type or mutant) in the right flank. 
In all untreated mice, in vivo tumor growth kinetics was very similar to that previously reported in the 
trial experiment, with a large tumor mass developing in the flank injected with control Hey3Met2 cells 
when compared to the small-sized tumors of RNASET2-overexpressing Hey3Met2 cells. By contrast, the 
tumor suppressing activity of wild type RNASET2 turned out to be largely impaired in clodronate treated 
mice (figure 19). 
Unfortunately, xenografts from mice injected with Hey3Met2-overxpressing RNASET2 mutant proved 
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Upper picture. Untreated mice were grafted in the left flank with Hey3Met2 control cells, carrying the pcDNA3 vector, 
whereas in the right flank Hey3Met2-overexpressing RNASET2 were injected. A considerably reduction of tumor mass is 
notable. 
Lower picture. Mice treated with the macrophage-depleting agent clodronate were grafted as before. RNASET2 wild type 
resulted strongly impaired in tumor suppression. 
Each group of transplanted animals (4 mice/group) was either macrophages depleted or mock treated in both flanks by 
subcutaneous injection of clodronate liposomes or vehicle alone (PBS) every 6 days, starting at day 2 of the tumor 
challenge. Animals were monitored twice a week for weight and tumor growth, and sacrificed when the mean tumor 
volume of one of the subcutaneous tumors reached a dimension of ≥ 800 mm
3
. 






At the end of observation period, mice were sacrificed and immunohistochemical characterization of the 
host cell infiltrate in tumor samples was performed. As shown in figure 20 (right panel), the lack of cells 
stained with the macrophage-specific marker CD68 confirmed the efficient depletion of macrophages in 
clodronate-treated mice, whereas these cells could be clearly detected in untreated animal injected with 
wild-type RNASET2-expressing cells (figure 20, left panel). Tissue macrophages are known to be 
endowed with a wide functional plasticity, which allows them to carry out both pro-tumoral and anti-
tumoral activities depending on microenvironmental cues (56). Therefore, we investigated the pattern of 
macrophage polarization within RNASET2-expressing tumor xenografts by carrying out IHC assays with 
markers known to discriminate the differentiation pattern of macrophages into either M1 and M2 
subtypes. Interestingly, most of the infiltrating macrophages were of the M1, iNOS-positive type, in 
keeping with the suggested role of this macrophage subpopulation in tumor suppression (57). These data 























Figure 20. Immunohistochemical characterization of the host cell infiltrate in tumor samples from mock- or 





inoculated with control or RNASET2-expressing Hey3Met2 clones were analyses by IHC with the macrophage lineage-
specific anti-CD68 glycoprotein antibody. The relative proportion of both M1 and M2 macrophage subpopulations in the 
tumours was also investigated by means of IHC with anti-iNOS (inducible Nitric Oxide Synthase) and anti-Dectin-1 
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3.4 Knockdown of RNASET2 
 
  Based on the data collected with the Hey3Met2 cell line, RNASET2 apparently behaves 
as a strong suppressor of ovarian cancer development. Thus, it is reasonable to assume that inactivation of 
this gene (either at the transcriptional level or by a mutational event within coding region of the gene) 
might represent a critical step in ovarian cancer progression. 
To further validate this hypothesis, ovarian cancer cell lines endowed with a low in vivo tumorigenic 
potential and expressing high endogenous RNASET2 levels might provide an ideal experimental model. 
Since the human ovarian cancer cell line OVCAR3 have the above mentioned features (50, 58), RNAi-
mediated silencing has been attempted in this cell line in order to validate the tumor suppressive role of 
RNASET2 in a second independent model. 
RNASET2-specific interfering and scrambled control sequences were defined in silico as described in 
material and methods and subsequently cloned in the lentiviral-derived pSicoR vector. Cultured 
OVCAR3 cells were then infected with recombinant lentiviral particles, yielding a stable and high 
efficiently silenced cell line, named OVCAR3::pSicoR-shRNASET2. In control cells, infected with the 
construct pSicoR-scrambled, the transcription of a mock interfering siRNA occurs but is predicted to 
leave RNASET2 expression unaffected. Indeed, western blot analysis of total cell extracts with an anti-





Figure 21. Characterization of RNASET2 knockdown by immunoblot 
Upper panel: intracellular lysates of OVCAR3 parental cell line (1), 
OVCAR3::pSicoR-shRNASET2 (2), OVCAR3::pSicoR-scrambled (3) 
detected with anti-RNASET2 polyclonal antibody. 
Lower panel: the same blot was probed with anti-α-tubulin monoclonal 





RNASET2-silenced and control clones were then isolated from cellular heterogeneous pools and they are 
currently under investigation in a wide panel of in vitro and in vivo assays. 
Up to date, growth curve and clonogenic assay have already been completed and showed no differences 















































These preliminary data are in keeping with the previously described for Hey3Met2 RNASET2-
overexpressing model, and further demonstrate the non-cell autonomous behavior of RNASET2 as a 















Figure 22. MTT proliferation assay 
Three independent clones of both OVCAR3::pSicoR-shRNASET2 and OVCAR3::pSicoR-scrambled are assayed for 
proliferation. 800 cells per clone are plated in 96-multiwell culture plate in triplicate and growth is monitored for 7 days, 













Figure 23. Clonogenic assay 
Cells were plated in 6-well culture plates (1x10
2
 cells per well) and following 14 days incubation, clones were stained with 
a methylene blue solution (1% methylene blue, 50% ethanol) and visible colonies were manually counted. 









Moreover, besides their use in validating the tumor suppressing activity for this gene, RNASET2-silenced 
OVCAR3 cells also provide an excellent experimental model to start investigating both the intracellular 
routing of RNASET2 and the mechanism(s) by which extracellular RNASET2 affects cell behavior. 
Indeed, on the basis of the “asymmetric” behavior observed by comparing the in vitro and in vivo 
properties, RNASET2 could be hypothesized to act as a chemokine in vivo either directly, by interacting 
with host immune cells, or indirectly, by triggering the production and secretion of inflammatory 
chemokines by the cancer cell itself. Under both assumptions, RNASET2 binding to the surface of a 
target cell would represent a critical step. Moreover, such putative binding to the cell surface could be 
followed by the internalization of bound RNASET2 within the target cell. Alternatively, RNASET2 could 
act as a strictly extracellular ligand and trigger an intracellular cascade without being internalized. 
To try to shed light on cell surface binding and trafficking, an immunogold localization assay has been 
performed on silenced OVCAR3 cells exposed to exogenous RNASET2. 
As shown in figure 23, whereas no RNASET2 signal could be detected in silenced OVCAR3 cells by 
transmission electron microscopy (T.E.M.) analysis, a complex localization pattern was found in the same 




















Figure 23. T.E.M. of silenced and parental OVCAR3 cells probed with polyclonal anti-RNASET2 
In silenced cells (A – A’) no signal is detected, whereas in parental OVCAR3 cells (B) a diffuse RNASET2 signal occurs. 










Exposing OVCAR3 silenced cells to conditioned medium of parental cells (enriched in secreted 
RNASET2) resulted in binding of the protein to cell surface, thus suggesting the occurrence of a cell 
surface ligand for this enzyme in OVCAR3 cells (figure 24). Moreover, internalization of RNASET2 was 
also demonstrated thus suggesting that binding to the cell surface might represent a limiting step for 
subsequent RNASET2 uptake. If confirmed by further experiment, these preliminary data might also 
unveil previously unexpected cell-autonomous mechanisms by which RNASET2 might affect cancer cell 































Figure 24. Membrane binding and internalization 
Exposing silenced OVCAR3 cells to conditioned medium resulted in an uptake of exogenous RNASET2. 
In A and B images a detail of membrane binding is appreciable. In C a widespread signal occurs, indicating the 




Furthermore, a detailed inspection of the photomicrographs revealed not only an intracellular localization 
pattern within vesicles, but strikingly a nuclear signal was also detected (figure 25). Again, this result 




































Figure 25. Subcellular localization 
Immunogold staining revealed a localization within vesicles (appreciable in A and B’) and electron dense structures (B” 




















  Abnormalities of the long arm of chromosome 6 are associated with several solid 
neoplasms and hematological malignancies (38-43). Given the broad spectrum of tumours associated with 
genetic alteration of this genomic region, it has been postulated that the latter could bear tumor suppressor 
genes playing a general role in tumorigenesis (38). Among the regions of chromosome 6q frequently 
deleted in tumours, 6q21 and 6q27 have been the focus of intensive investigations in recent years. In the 
latter region, our group mapped the RNASET2 gene, which represents the first human member of the 
Rh/T2/S family of ribonucleases. 
This gene was shown to be ubiquitously expressed in normal tissues, although at variable levels, but was 
found to be down-regulated at the RNA level in several ovarian primary tumours and cell lines and in 
lymphoid neoplasms. Together with its localization in 6q27, these evidences suggested a role for 
RNASET2 in tumor suppression (50). 
In a further functional analysis, our group reported a direct evidence for RNASET2-mediated control of 
tumor growth in vivo. In this study, the low-expressing Hey3Met2 human ovarian cancer cell line was 
stably transfected with RNASET2 cDNA, and inoculation of transfected clones into athymic mice 
resulted in a clear inhibition of tumor development. Interestingly, an RNASET2 mutant lacking catalytic 
activity also showed a similar or even more increased inhibition of tumorigenesis when compared to the 
wild type protein, suggesting that ribonuclease activity is not involved in control of tumor suppression 
and metastasis (51). The more efficient tumour suppressor activity of the mutant form was an intriguing 
finding that still has to be cleared. Although this observation could be simply explained by a slight 
difference in the expression levels in mutant compared to wild type RNASET2-expressing clones 
(assuming that both protein forms display the same tumor suppressive activity), we cannot rule out more 
complex mechanisms. Therefore, this issue will likely be definitively solved when further structural and 
functional investigations of both wild type and mutant RNASET2 will be performed. However, it is worth 
noting that a catalytically independent biological role has also been reported for other members of the T2 
family (33). 
The finding of a tumor suppressing ribonuclease is not unexpected, since an oncosuppressive role has 
already been demonstrated for other genes encoding for this class of enzymes. For example, human 
ribonuclease L (RNase L), which maps to 1q25, has been linked to susceptibility to hereditary prostate 
cancer (HPC1), and some its variants were associated with aggressive metastatic prostate neoplasia (59, 
60). 
Moreover, many examples of cytotoxic ribonucleases endowed with anticancer activity belonging to A 
family have been reported. The most representative are BS-RNase and Onconase, known to be highly 
cytotoxic to cancer cells. The former has been shown to possess anticancer activity against several tumor 
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types, including thyroid carcinoma and neuroblastoma cells (17-20), whereas the latter is currently under 
phase III clinical trials for unresectable malignant mesothelioma (14). 
Significantly, a strong antitumor activity has also been described for a fungal member of T2 family 
ribonucleases, namely ACTIBIND. Unrelated to its RNase activity, ACTIBIND binds actin filaments in 
vitro, resulting in altered actin organization and cell morphology. This is in turn reflected in reduced in 
vitro colony formation and motility of several tumor cell lines. In vivo, ACTIBIND inhibits growth and 
metastasis in colon cancer and melanoma mouse model (36, 37) and inhibits angiogenesis both in vitro 
and in vivo by directly competing with angiogenin. 
 
With the aim to further understanding the mechanisms at the basis of tumor suppressor activity mediated 
by RNASET2, a comparative analysis by means in vitro and in vivo assays has been carried out in this 
work. 
Thus, in order to verify if RNASET2 could control tumor development at cellular level (i.e. in a cell-
autonomous manner), several in vitro test were carried out with Hey3Met2 RNASET2-overexpressing 
clones. By comparing several parameters such as cell proliferation, apoptosis, clonogenicity and growth 
on semisolid media, it was found that RNASET2 had no effect on these cellular features in vitro. 
Noteworthy, at least for proliferation and clonogenic assay, the same results was obtained in the 
OVCAR3 knockdown RNASET2 model, further supporting the hypothesis of a non-cell autonomous 
behavior. 
On the other hand, when the same Hey3Met2 clones were investigated in vivo we could easily confirm 
the previous evidence of a strong oncosuppressive activity carried out by this gene. 
This sharp difference of RNASET2 behavior between the two experimental models was not completely 
unexpected, since other tumor suppressor genes have been reported to display such “asymmetric” 
behavior in vitro/in vivo in the control of malignancy (11, 12). Indeed, based on this particular feature a 
new class of tumor suppressor genes has been recently proposed, namely the tumor antagonizing- or 
malignancy suppressor-genes (TAGs/MSGs) (2). These genes are functionally defined by having no 
effect on tumor growth in vitro, whereas their function is clearly detected in vivo and is likely mediated 
by the establishment of a cross-talk between the cancer cell and the tumor microenvironment (3, 4, 5). 
Among tumor antagonizing genes, worth mentioning are the hyaluronidase HYAL1 and HYAL2 genes 
and the WWOX gene. 
HYAL1 and HYAL2 are located in the minimal region of homozygous deletion for lung cancer (LUCA) 
in the 3p21 region and encode for enzymes involved in the catabolism of hyaluronic acid. Inactivation of 
one of the two genes lead to accumulation of hyaluronan in the extracellular compartment, which in turn 
enhances anchorage independent tumor cell growth (11). Since the product of both genes have a potential 
to influence intercellular interactions, their impairment inhibit microenvironmental control mechanisms 
that normally protect the host from tumor growth. 
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As far as the WWOX gene is concerned, restoration of its expression in human PE01 ovarian cancer cells 
causes reduction of tumor development in SCID mice in vivo but not in vitro (12). By altering the levels 
of membrane-associated integrin α3, WWOX-overexpressing cells show reduced adhesion to the 
extracellular matrix component fibronectin that in turn is reflected in a reduced survival rate in vivo. 
 
Current cancer research is increasingly focusing on the study of tumour microenvironment, which is the 
complex system of cells and extracellular matrix surrounding the malignant milieu. Several recent reports 
suggest that carcinogenesis should be regarded as phenomena occurring in tissues and not just in 
individual cancer cells (6-10). Indeed, the tumour microenvironment is known to strongly influence the 
propensity of neoplastic cells to proliferate in vivo, either through direct contact between tumour and 
stromal cells or by means of soluble ligands interacting with cell receptors. More specifically, the genes 
whose products might participate in the regulation of tumour interaction with stromal cells and 
extracellular matrix are predicted to be involved in three types of processes: 1) response to differentiation-
inducing signals in vivo; 2) response to microenvironmental signals; 3) angiogenesis inhibition (4). 
Strikingly, the detailed histochemical examination of tumour sections isolated from athymic mice 
inoculated with RNASET2-transfected ovarian cancer cells showed a completely different tissue 
architecture with respect to controls, pointing out a remodeling of surrounding stromal environment 
exerted by RNASET2. Particularly interesting was the finding of a massive infiltrate of host cells, with 
abundant deposition of connective tissue and collagen fibers in RNASET2-overexpressing tumors. 
Morphological and histochemical analyses indicated this host cellular population infiltrating the 
neoplastic mass was made of cells belonging to monocyte/macrophages lineage. 
The macrophage represent a rather versatile cell type displaying pleiotropic biological roles which 
includes antigen presentation, target cell cytotoxicity, removal of debris and tissue remodeling, regulation 
of inflammation, induction of immunity, thrombosis and various forms of endocytosis (56). 
In the frame of tumour development, tumour-associated macrophages (TAMs) have a wide range of 
functions which could affect diverse aspects of neoplastic growth such as angiogenesis, matrix deposition 
and remodeling, modulation of tumor cell growth (both enhancement and inhibition) and neoplastic cell 
death (cytotoxicity, apoptosis) (57, 61). 
In this conceptual framework, we turned our attention to the putative mechanisms underlying RNASET2-
mediated tumor suppression. To this aim, three main processes were investigated such as proliferation 
rate, apoptosis and vascularization. Whereas the latter seemed to be similar in all analyzed specimens, a 
decreased proliferation rate in addiction to markedly cell death was observed in RNASET2-transfected 
tumors, suggesting that the synergistic effect of these two parameters could be at the basis of the strong 
decrease of tumor mass observed. 
The functional role of macrophages infiltration in the control of tumorigenicity was also directly 




 mouse model. 
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Indeed, in macrophage-depleted mice the tumor growth kinetics of control and RNASET2-expressing 
cells were very similar, whereas in untreated mice large tumor masses developed in the flank injected 
with control Hey3Met2 cells compared to the small-sized tumors of RNASET2-overexpressing 
Hey3Met2 cells, as previously reported.  





mouse model.  
Indeed, by expressing different functional programs in response to particular conditions present within the 
tumour microenvironment (62) macrophages possess activities that can either prevent the establishment 
and spread of tumor cells or support tumor progression and metastatization. This ambivalent relationship 
between macrophages function and cancer is due to the high functional plasticity of these cells that has 
been mentioned before. 
Such different polarization of TAMs is also referred as M1-“classical activated” vs. M2-“ alternatively 
activated” phenotype, indicating the anti-tumoral and pro-tumoral properties respectively. 
“Classical activated” M1 type macrophages participate to the innate host defense against pathogens. They 
are stimulated by microbial agents, interferon-γ and TNF-α and are generally considered potent effector 
cells against microorganisms and tumor cells by means of pro-inflammatory cytokines secretion, in 
addition to a high production of toxic products such as nitric oxide (NO) and reactive oxygen 
intermediates (ROI). Alternatively, activated macrophages (M2) are normally involved in wound healing, 
where they participate in tissue remodeling and secretion of growth factors that stimulate fibroblast 
proliferation, migration, and extracellular matrix formation. Nevertheless, in the context of a growing 
tumor and under different stimuli such as hypoxia and several inducers (such as cytokines IL-10, IL-4 and 
glucocorticoid hormones), M2 macrophages can promote tumor growth by producing growth factors that 
enhance cancer proliferation (such as PDGF and EGF), dissemination (metalloproteinases) and 
angiogenesis via VEGF production (63). 
In RNASET2-expressing tumors both M1 iNOS (inducible Nitric Oxide Synthase) positive macrophages 
and M2-dectin1 positive macrophages were found, with a prevalence of M1 cells, in keeping with the 
anti-tumor activity owned by these cells. The presence of M2 type could be explained by virtue of the 
high functional plasticity of macrophages which are able to finely modulate their programs in response to 
different microenvironmental conditions. Indeed, dynamic changes of the tumor microenvironment that 
occur during the transition from early neoplastic events toward advanced tumor stages (such as hypoxia, 
glucose levels, pH and tumor cells products including extracellular matrix components, IL-10 and CSF-1 
(Colony Stimulating Factor 1) that are thought to occur, drive an M1-to-M2 switch (63). 
Taken together, our data suggest that RNASET2 most likely could act as a tumor antagonizing gene, by 
playing an inflammatory-like role. 
Significantly, functional interactions between enzymes endowed with RNase activity and immune system 
cells is not unexpected. As an example, alarmins are defined as endogenous mediators rapidly released by 
cells of the host innate immune system in response to infection and/or tissue injury, which possess the 
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dual activity of recruiting and activating dendritic cells and consequently enhance antigen-specific 
adaptive immune responses. 
Mammalian eosinophil granules contain an antimicrobial protein known as eosinophil-derived neurotoxin 
(EDN), which belongs to the RNase A superfamily and has antiviral and chemotactic activities, inducing 
migration and maturation of dendritic cells. The latter enhance the adaptive immune system response by 
stimulating lymphocytes T helper maturation (Th2 polarization) (64, 65). 
Another connection between RNases and immune system arises from a T2 ribonuclease present in the 
eggs of the worm Schistosoma mansoni, a trematode parasitic of human beings. Eggs secrete a 
glycoprotein termed omega-1, which is a member of RNaseT2 family. Recent data (66) showed that both 
in vitro and in vivo omega-1 is the major component in priming dendritic cells for Th2 polarization of 
CD4+ T cells during infection. However, this function appears to depend on the RNase activity of omega-
1, as inactivation of the ribonuclease activity inhibits the Th2-polarizing function (67). 
The assumption that RNASET2 could act as a signaling molecule is also supported by preliminary 
immunolocalization studies carried out with OVCAR3 silenced cells. In this view, two main possible 
scenarios can be proposed. In the first, RNASET2 would act as a chemokine-like ligand, binding directly 
the host immune cells to trigger an intracellular response; in the second scenario, RNASET2 would elicit 
the production of an inflammatory chemokine(s) by the cancer cell itself. By exposing RNASET2-
silenced ovarian cancer cells to conditioned medium enriched in exogenous RNASET2, we could observe 
both the binding of the protein to cell surface and its subsequent internalization, two critical steps 
involved in cell-ligand interactions. 
Although this assay opens up the possibility of an autocrine trafficking of RNASET2 and thus supports 
the second hypothesis, we cannot rule out the possibility that RNASET2 could also act as a signaling 
molecule by itself, and further studies (e.g. monocytes chemoattractant assay with recombinant protein) 
will be carried out to investigate this issue. 
Finally, the putative autocrine pathway observed in cancer cells raised the question whether RNASET2 
could have an additional cell-autonomous activity. 
Recent works (35, 68) have reported that during oxidative stress the yeast RNASET2 orthologue Rny1p is 
released from the vacuole to the cytoplasm, where it cleaves cytoplasmic tRNAs and rRNAs. Moreover, 
Rny1p also modulates yeast cell survival during oxidative stress, resulting in reduced cell viability and 
apoptosis, and this effect is carried out independently of its catalytic activity, arguing that Rny1 has a 
second function involving promotion of cell death, unrelated to its ability to cleave RNA. Interestingly, 
by means functional complementation, RNASET2 was found to restore tRNA cleavage and confer a 
similar loss of viability and apoptosis susceptibility under stress conditions as the endogenous protein. 
Hence, the apoptotic phenotype triggered in vivo by RNASET2 might be ascribed not only to macrophage 
recruitment and activation but perhaps to RNASET2 cell-autonomous effects within tumor cells as well, 











Cell cultures, transfections and infections 
The Hey3Met2 and OVCAR3 human ovarian cancer cell lines were maintained in DMEM-F12 medium, 
supplemented with 10% FBS and 2 mM L-glutamine (Gibco) and grown at 37 °C in a 5% CO2 
atmosphere. 
For transfection experiments, Hey3Met2 cells were plated in 6-well plates the day before experiment, to 
reach 80% confluence at transfection, which was performed with Lipofectamine 2000 (Invitrogen), 
according to the manufacturer’s instructions. Forty-eight hours after transfection, cells were trypsinized 
and transferred into 100 mm cell culture plates and selected with 300µg/ml G418 (Invitrogen). After two 
weeks, single transfected clones were isolated using cloning rings. A western blot analysis was carried out 
with a rabbit polyclonal anti-RNASET2 antibody (1:1000) on total protein extract (30 µg/lane) from each 
clone, to evaluate the level of RNASET2 expression. Clones displaying the highest RNASET2 expression 
levels were selected for experiments. 
For infection experiments, packaging cell line HEK 293T were transfected with pSicoR-shRNASET2 or 
control construct pSicoR-scrambled in addiction to viral components (GAG-POL, ENV). The day after 
transfection, HEK 293T cells supernatant is collected, filtered with 0.45µm pore filter and used to infect 
OVCAR3 cells. Forty-eight hours after infection cells are selected with 1.5µg/ml puromycin (Sigma). 
Cell cultures were routinely checked for the presence of contaminating mycoplasma by a nested PCR 
method described in Tang et al. (69). 
 
In vitro cell based assays 
Growth curve 
In vitro cell growth curves were assembled by plating 4000 cells in a 24-well culture plate and counting 
viable cells daily in triplicate on a Burker chamber for 8 days. Growth curve is obtained plotting the log 
of cell number against time. 
Doubling time is determined using the formula Tc = (0.3T)/log (A/A0), where “A” is the number of cells 
counted at “T” time, and “A0” is the initial number of seeded cells. Values of “T” and “A” are considered 
in the portion of semi-log plot where the shape of the curve is a straight line. 
 
BrdU incorporation and apoptosis 
For BrdU incorporation assay, Hey3Met2 cells were plated on coverslips in 6-well plates until they 
reached 70% confluence and are in logarithmic phase of cell division. Subsequently are pulsed with a 
10μM solution of BrdU for 1 hour and according to BrdU in-Situ Detection Kit (BD) are fixed, 
permeabilized and labeled with biotinylated anti-BrdU antibody 1:10, followed by streptavidin-HRP 
conjugated incubation. Immunostaining is then performed with diaminobenzidine (DAB) as substrate. For 
negative controls, BrdU antibody was omitted. 
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For apoptosis detection cells are plated as before and fixed in 4% paraformaldehyde. According to 
DeadEnd™ colorimetric TUNEL (Promega) cells are permeabilized and incubate with biotinylated buffer 
mix enzyme containing TdT polymerase and nucleotides at 37°C for 60 minutes. Immunostaining is then 
performed with DAB as substrate. For negative controls, Terminal Deoxynucleotidyl Transferase 
Recombinant (rTdT) was omitted. 
 
Clonogenic assay, soft agar growth and adhesion test 





Following a 10-14 days incubation, clones were stained with methylene blue solution (1% methylene blue 
w/v, 50% ethanol) and visible colonies were manually counted. Each clone was assayed in triplicate. 
In order to estimate colony formation in anchorage independent manner, two-layers soft agar test was 
performed. For each clone 100 cells are resuspended in an upper layer of 0.3% Bacto-Agar in DMEM 
F12 and 20% fetal bovine serum and then plated over an under layer of 0.6% Bacto-Agar in DMEM F12 
and 20% fetal bovine serum in a 12 well culture plate. Each clone was assayed in triplicate and colonies 
after 14 days were counted. 
Adhesion test has been carried out plating Hey3Met2 clones onto 96-well matrigel coated (50µg/ml, 
Sigma) (5x10
3
 cells/clone, 10 wells/clone). Four hours after seeding cells, growth media is removed and 
cells are fixed/stained with 37% formaldehyde and 0.75% (w/v) crystal violet solution. After several 
washes, dye is eluted in 50% ethanol, 0.1% acetic acid solution and absorbance at 595 nm is measured. 
 
MTT proliferation assay 
Silenced and control OVCAR3 clones are seeded in triplicate in 96-well plate (8x10
2
 cells/well, one plate 
per day) and growth in monitored for 7 days. According to the manufacturer’s instructions (CellTiter 96
®
 
Non-Radioactive Cell Proliferation Assay, Promega) 15µl of tetrazolium salt is added to each well and 
formazan product is detected after 4 hours of incubation, by 96-well plate reader at 595 nm. 
 
In vivo xenograft studies 




(3 animals/clone) were 
grafted by means subcutaneous injection with 5x10
6 
Hey3Met2 cells (control or Hey3Met2 cells 
expressing wild-type RNASET2 or RNASET2 mutant), resuspended in 0.15 ml of growth medium and 
0.15 ml of matrigel (Sigma). Animals were monitored twice a week for weight and tumor growth 
(measuring three perpendicular diameters), and sacrificed when the mean tumor volume of control mice 
reached a dimension of ≥1000 mm
3
. 




 mice was carried out using clodronate liposomes (Roche). 
Four animals/clone were injected subcutaneously with control Hey3Met2 cells in the left flank and with 
Hey3Met2 cells expressing either wild-type or catalytically impaired mutant RNASET2 in the right flank. 
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Each group of transplanted animals was either macrophage-depleted or not by subcutaneously injection in 
both flanks of clodronate liposomes (50ml/flank) every 6 days, starting at day -2 of the tumor challenge. 
Mice were monitored twice a week for weight and tumor growth, and sacrificed when the mean tumor 
volume reached a dimension of 800 mm
3
. Animals were maintained in a pathogen–free facility and 
treated in accordance with the European guidelines under the approval of the Ethical Committee of the 
Istituto San Raffaele of Milan. 
 
Histological and immunohistochemical assays 
Harvested tumors were either fixed in buffered 4% formalin either embedded in OCT and frozen in liquid 
nitrogen. 3µm paraffin sections were either stained with hematoxylin and eosin or with Masson’s 
trichrome staining (Sigma) for morphological analysis. Cryosections were immunostained with the with 
the following primary antibodies after antigen retrieval: anti-RNASET2 (1:100); rabbit anti-cleaved 
caspase-3 (1:20, Santa Cruz Biotechnology) rat anti-mouse CD11b (1:50, Pharmingen), rat anti-human 
Ki-67 (1:100, Dako) and rat-anti F4/80 (1:50, Pharmingen). The immunoreactions were revealed either by 
biotinylated-conjugated anti-rat antibody (Vector), horseradish peroxidase-conjugated streptavidin either 
by rabbit or rat on rodent HRP-polymer (Biocare Medical) and using DAB as chromogenic substrate 
(Biogenex). Slides were counterstained with hematoxylin. Photomicrographs were taken using the 
AxioCam HRc (Zeiss) with the AxioVision System 6.4. 
To evaluate blood vessel density in tumor samples, cryosections were treated with 50mM levamisole to 
block endogenous alkaline phosphatase. A mouse anti-human PECAM-1 (CD31) antibody (1:20, Dako) 
was then incubated for 1h at 37°C, followed by a 45 min treatment with a secondary goat anti mouse AP-
conjugated antibody (1:200). The signal was detected with BCIP/NBT Alkaline Phosphatase Substrate 
Solution (Sigma). Control reactions were carried out by omitting the primary antibody. 
For CISH analysis, the ZytoDot probe kit (Histo-Line) was used to hybridize a biotinylated murine 
chromosome Y-specific centromeric probe to serial sections of Hey3Met2-derived tumors according to 
the manufacturer’s instructions. 
Macrophages populations in clodronate-treated and control animals were detected on cryosections 
obtained as described above and treated with 0.3% H2O2 in PBS to remove endogenous peroxidase. 
Washed sections were incubated for 1h at 37°C with the following biotinylated primary antibodies: rat 
anti-mouse CD68 (1:100, HyCult Biotechnology), rat anti-mouse Dectin-1 (1:50 Cell Sciences) and rabbit 
anti-mouse iNos-2 (1: 10, Santa Cruz Biotechnology). The washed specimens were incubated for 30 min 
at room temperature with streptavidin-peroxidase (Dako), washed , and signal was detected with 0.05% 
DAB and 0.03% H2O in PBS. Sections were counterstained with hematoxylin. Coverslips were mounted 





For immunogold cytochemistry, samples were fixed for 2h at 4°C with 4% paraformaldehyde and 0.5% 
glutaraldehyde in PBS, dehydrated in ethanol series and impregnated in Epon-Araldite 812 mixture. After 
etching with 3% NaOH in absolute ethanol, ultrathin sections (80nm in thickness) were placed on 
conventional nickel grids and incubated overnight at 4°C with primary rabbit polyclonal anti-human 
RNASET2 diluted 1:40 in saturation buffer (1% NGS, 1% ovalbumin in TBS). Primary antibodies were 
visualized by immunochemical staining with secondary goat anti-rabbit IgG (H+L)-gold conjugate 
antibodies (GE Healthcare Amersham, Buckingamshire, UK ) (particle size 15nm) diluted 1:100 
(incubation 2h at room temperature). Control sections were incubated in saturation buffer and then with 
secondary antibodies alone. Samples were counterstained with 2% uranyl acetate in water and observed 
under electron microscopy Jeol 1010 EX electron microscope. 
 
Western blot 
Total protein extracts were obtained by scraping cells with PBS-EDTA 10mM, and lyse them with 5mM 
EDTA, 0.5% NP40, 0.5% Triton X-100 in PBS buffer, supplemented with a mixture of protease 
inhibitors (PMSF, benzamidine, aprotinin, and leupeptin). Quantitation of total protein was performed 
with Bradford reagent (BioRad), using bovine serum albumin as standard. Intracellular lysates were 
loaded on a 13% SDS-PAGE (30µg/lane) and then transferred to a nitrocellulose membrane which was 
blocked in 4% w/v of non-fat milk in PBS-T (0.1% Tween 20 in PBS buffer) and probed with rabbit anti-
RNASET2 (1:1000) or mouse anti-α-tubulin (1:1000 Sigma). Immunoblot analysis was then performed 
according to standard procedures with HRP-conjugated secondary antibodies (anti-rabbit 1:900 and anti-
mouse 1:900, Pierce) and detected with the chemiluminescent substrate SuperSignal West Dura (Pierce). 
 
Plasmid vectors and sequences design for RNA interference 
Several interfering sequences for RNASET2 gene have been generated with pSicoOligomaker 1.5 
program, and were aligned with BLAST algorithm against the whole transcriptome database, in order to 
choose the only sequence able to target uniquely RNASET2 without alter other transcripts. Scrambled 
sequence were designed having the same GC% content of the interfering sequence but does not match 
with any transcript present in database. 
Interfering and scrambled oligonucleotides are constituted by a short sequence of 19 nucleotides (directly 
involved in pairing with RNA, in the box below) inserted within a wider nucleotide context required for 





Interfering sequence (sense strand) 
5’ TGCAGAAGCCTGGAACTCTATTCAAGAGATAGAGTTCCAGGCTTCTGCTTTTTTC 
Scrambled sequence (sense strand) 
5’ TGAGTCGACCGAACAGTCTATTCAAGAGATAGACTGTTCGGTCGACTCTTTTTTC 
Sense and antisense strands of both oligonucleotides were annealed in appropriate buffer (100 mM 
potassium acetate, 10mM HEPES-KOH pH 7, 2mM Magnesium acetate), slowly cooling down the 
temperature from 70°C to 4°C (1°C/min). Annealed oligonucleotides are then cloned in XhoI/HpaI 
digested pSicoR vector. 
pSicoR vector (plasmid for Stable RNA Interference, COnditional Reverse) is a lentiviral-derived vector 
for stable expression of shRNAs (70) that efficiently drives short hairpin transcription under the control of 
RNA polymerase III specific-promoter U6. pSicoR vector could be either transfected in target cells or 
delivered by means infection and Lox-P sites flanking the short hairpin expression cassette allow to 
remove it by Cre-lox-P mediated recombination. 
 
Statistical analysis 
The results from in vitro and in vivo assays with Hey3Met2 cells were evaluated by means of one-way 
ANOVA test with fixed p value ≤0.05, whereas the Student t-test was used to analyze in vitro assays 
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